Skip to main content

Advertisement

Sections

Page 1 of 40

  1. B7-H3 and B7-H4 are highly expressed by many human malignancies making them attractive immunotherapeutic targets. However, their expression patterns and immune contexts in epithelial ovarian cancer have not be...

    Authors: Heather L. MacGregor, Azin Sayad, Andrew Elia, Ben X. Wang, Sarah Rachel Katz, Patricia A. Shaw, Blaise A. Clarke, Sarah Q. Crome, Celine Robert-Tissot, Marcus Q. Bernardini, Linh T. Nguyen and Pamela S. Ohashi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:357

    Content type: Research article

    Published on:

  2. Acute interstitial nephritis is an immune-related adverse event that can occur in patients receiving immune checkpoint inhibitor therapy. Differentiating checkpoint inhibitor-associated acute interstitial neph...

    Authors: David Qualls, Harish Seethapathy, Halla Bates, Shahein Tajmir, Pedram Heidari, Paul Endres, Kerry Reynolds, Donald Lawrence and Meghan Sise

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:356

    Content type: Case report

    Published on:

  3. The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a prog...

    Authors: Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:354

    Content type: Position article and guidelines

    Published on:

  4. Cytokines of the common γ-chain receptor family such as IL-15 are vital with respect to activating immune cells, sustaining healthy immune functions, and augmenting the anti-tumor activity of effector cells, m...

    Authors: Alexandra Berger, Sarah J. Colpitts, Melanie S. S. Seabrook, Caren L. Furlonger, Maura B. Bendix, Joshua M. Moreau, William M. McKillop, Jeffrey A. Medin and Christopher J. Paige

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:355

    Content type: Research article

    Published on:

  5. Patients with chronic viral infections including human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of developing malignancies. The safety and efficacy of ICI the...

    Authors: Neil J. Shah, Ghassan Al-Shbool, Matthew Blackburn, Michael Cook, Anas Belouali, Stephen V. Liu, Subha Madhavan, Aiwu Ruth He, Michael B. Atkins, Geoffrey T. Gibney and Chul Kim

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:353

    Content type: Research article

    Published on:

  6. Following publication of the original article [1], the authors have reported that an author’s name has been incorrectly spelled: the correct given name is Anne-Marie (instead of Anne-Maria P) and family name i...

    Authors: Hamzah Abu-Sbeih, Lauren Nicholas Herrera, Tenglong Tang, Mehmet Altan, Anne-Marie Chaftari, Pablo C. Okhuysen, Robert R. Jenq and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:352

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:242

  7. OX-40 co-stimulatory signaling plays a role in mounting anti-tumor immune responses and clinical trials targeting this pathway are ongoing. However, the association of with OX-40 protein expression with clinic...

    Authors: Erminia Massarelli, Vincent K. Lam, Edwin R. Parra, Jaime Rodriguez-Canales, Carmen Behrens, Lixia Diao, Jing Wang, Jorge Blando, Lauren A. Byers, Niranjan Yanamandra, Sara Brett, Peter Morley, Padmanee Sharma, James Allison, Ignacio I. Wistuba and John V. Heymach

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:351

    Content type: Short report

    Published on:

  8. Anti-cancer therapy is more successful when it can also induce an immunogenic form of cancer cell death (ICD). Therefore, when developing new treatment strategies, it is extremely important to choose methods t...

    Authors: Victoria D. Turubanova, Irina V. Balalaeva, Tatiana A. Mishchenko, Elena Catanzaro, Razan Alzeibak, Nina N. Peskova, Iuliia Efimova, Claus Bachert, Elena V. Mitroshina, Olga Krysko, Maria V. Vedunova and Dmitri V. Krysko

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:350

    Content type: Research article

    Published on:

  9. Following publication of the original article [1], the authors have reported that Fig. 2 and Additional file 1: Figure S1, S2 partially show red scripts.

    Authors: Philipp Metzger, Sabrina V. Kirchleitner, Michael Kluge, Lars M. Koenig, Christine Hörth, Carlotta A. Rambuscheck, Daniel Böhmer, Julia Ahlfeld, Sebastian Kobold, Caroline C. Friedel, Stefan Endres, Max Schnurr and Peter Duewell

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:349

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:288

  10. Although several therapeutic options for patients with renal cell carcinoma (RCC) have been approved over recent years, including immune checkpoint inhibitors, considerable need remains for molecular biomarker...

    Authors: Rui Wang, Junying Zheng, Xiao Shao, Yuko Ishii, Amit Roy, Akintunde Bello, Richard Lee, Joshua Zhang, Megan Wind-Rotolo and Yan Feng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:348

    Content type: Short report

    Published on:

  11. Human (gamma delta) γδ T cells are unconventional innate-like lymphocytes displaying a broad array of anti-tumor activities with promising perspectives in cancer immunotherapy. In this context, Vδ2pos T cells rep...

    Authors: Elena Bruni, Valentina Cazzetta, Matteo Donadon, Matteo Cimino, Guido Torzilli, Gianmarco Spata, Gloria Leonardi, Francesco Dieli, Joanna Mikulak and Domenico Mavilio

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:347

    Content type: Short report

    Published on:

  12. Inhibitors targeting VEGF and VEGFR are commonly used in the clinic, but only a subset of patients could benefit from these inhibitors and the efficacy was limited by multiple relapse mechanisms. In this work,...

    Authors: Xuyao Zhang, Yichen Wang, Jiajun Fan, Wei Chen, Jingyun Luan, Xiaobin Mei, Shaofei Wang, Yubin Li, Li Ye, Song Li, Wenzhi Tian, Kai Yin and Dianwen Ju

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:346

    Content type: Research article

    Published on:

  13. BackgroundGenetic instability is known to relate with carcinogenesis by providing tumors with a mechanism for fast adaptation. However, mounting evidence also indicates causal relation between genetic instabil...

    Authors: Guim Aguadé-Gorgorió and Ricard Solé

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:345

    Content type: Research Article

    Published on:

  14. Unlike some adult cancers, most pediatric cancers are considered immunologically cold and generally less responsive to immunotherapy. While immunotherapy has already been incorporated into standard of care tre...

    Authors: Julie Voeller, Amy K. Erbe, Jacob Slowinski, Kayla Rasmussen, Peter M. Carlson, Anna Hoefges, Sabrina VandenHeuvel, Ashley Stuckwisch, Xing Wang, Stephen D. Gillies, Ravi B. Patel, Alvin Farrel, Jo Lynne Rokita, John Maris, Jacquelyn A. Hank, Zachary S. Morris…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:344

    Content type: Research article

    Published on:

  15. Predicting metastasis in melanoma patients is important for disease management and could help to identify those who might benefit from adjuvant treatment. The aim of this study was to investigate whether the t...

    Authors: Nikolaus B. Wagner, Benjamin Weide, Mirko Gries, Maike Reith, Kathrin Tarnanidis, Valerie Schuermans, Charlotte Kemper, Coretta Kehrel, Anne Funder, Ramtin Lichtenberger, Antje Sucker, Esther Herpel, Tim Holland-Letz, Dirk Schadendorf, Claus Garbe, Viktor Umansky…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:343

    Content type: Research article

    Published on:

  16. Expressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine secretion and enhanced effector function. Targeting 4-1BB/CD137 ...

    Authors: Ezra E. W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa L. Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig B. Davis, Francesca Toffalorio, Aron Thall and Steven F. Powell

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:342

    Content type: Research article

    Published on:

  17. Deciphering the correlation between immune-related adverse events (irAEs) categorized by organ system class and clinical benefit of immunotherapy is critical for clinical practice. The aim of this study is to ...

    Authors: Puyuan Xing, Fan Zhang, Guoqiang Wang, Yu Xu, Chengcheng Li, Shouzheng Wang, Yiying Guo, Shangli Cai, Yan Wang and Junling Li

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:341

    Content type: Review

    Published on:

  18. Accumulating preclinical data indicate that targeting the SIRPα/CD47 axis alone or in combination with existing targeted therapies or immune checkpoint inhibitors enhances tumor rejection. Although several CD4...

    Authors: Erik Voets, Marc Paradé, David Lutje Hulsik, Sanne Spijkers, Wout Janssen, Joost Rens, Inge Reinieren-Beeren, Gilbert van den Tillaart, Sander van Duijnhoven, Lilian Driessen, Maurice Habraken, Peter van Zandvoort, Joost Kreijtz, Paul Vink, Andrea van Elsas and Hans van Eenennaam

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:340

    Content type: Research article

    Published on:

  19. Regulatory T (Treg) cells have an immunosuppressive function in cancer, but the underlying mechanism of immunosuppression in the tumor microenvironment (TME) is unclear.

    Authors: Hye Ryun Kim, Hyo Jin Park, Jimin Son, Jin Gu Lee, Kyung Young Chung, Nam Hoon Cho, Hyo Sup Shim, Seyeon Park, Gamin Kim, Hong In Yoon, Hyun Gyung Kim, Yong Woo Jung, Byoung Chul Cho, Seong Yong Park, Sun Young Rha and Sang-Jun Ha

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:339

    Content type: Research article

    Published on:

  20. Cutaneous squamous cell carcinoma (cSCC) is not uncommon in association with indolent malignancies that were treated with prior radiotherapy and after allogenic bone marrow transplantation. On the other hand, ...

    Authors: Karam Khaddour, Amy Musiek, Lynn A. Cornelius, Farrokh Dehdashti, Peter Westervelt, Ryan Fields and George Ansstas

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:338

    Content type: Case report

    Published on:

  21. Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to describe th...

    Authors: Guillaume Manson, Alexandre Thibault Jacques Maria, Florence Poizeau, François-Xavier Danlos, Marie Kostine, Solenn Brosseau, Sandrine Aspeslagh, Pauline Du Rusquec, Maxime Roger, Maud Pallix-Guyot, Marc Ruivard, Léa Dousset, Laurianne Grignou, Dimitri Psimaras, Johan Pluvy, Gilles Quéré…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:337

    Content type: Research article

    Published on:

  22. Immune checkpoint inhibitors (ICPis) have revolutionised the treatment of melanoma by significantly increasing survival rates and disease control. However, ICPis can have specific immune-related adverse events...

    Authors: Vincent Pillonel, Vincent Dunet, Andreas F. Hottinger, Gregoire Berthod, Luis Schiappacasse, Solange Peters, Olivier Michielin and Veronica Aedo-Lopez

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:336

    Content type: Case report

    Published on:

  23. Following publication of the original article [1], the authors reported that authors’ given and family names haven been incorrectly tagged.

    Authors: Anastasia Saade, Audrey Mansuet-Lupo, Jennifer Arrondeau, Constance Thibault, Mariana Mirabel, François Goldwasser, Stéphane Oudard and Laurence Weiss

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:335

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:266

  24. Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. With the exception of a few candidate biomarkers, the prognostic role of soluble immune checkpoint-related proteins in ...

    Authors: Qinchuan Wang, Jinhua Zhang, Huakang Tu, Dong Liang, David. W. Chang, Yuanqing Ye and Xifeng Wu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:334

    Content type: Research article

    Published on:

  25. Hepatocellular carcinoma (HCC) is the second deadliest cancer worldwide, due to its high incidence and poor prognosis. Frequent initial presentation at advanced stages along with impaired liver function limit ...

    Authors: Marc Hilmi, Cindy Neuzillet, Julien Calderaro, Fouad Lafdil, Jean-Michel Pawlotsky and Benoit Rousseau

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:333

    Content type: Review

    Published on:

  26. Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focus...

    Authors: Paolo A. Ascierto, Carlo Bifulco, Luigi Buonaguro, Leisha A. Emens, Robert L. Ferris, Bernard A. Fox, Greg M. Delgoffe, Jérôme Galon, Cesare Gridelli, Marco Merlano, Paul Nathan, Kunle Odunsi, Hideho Okada, Chrystal M. Paulos, Sandro Pignata, Kurt A. Schalper…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:332

    Content type: Review

    Published on:

  27. CD8+ T cells differentiate into exhausted status within tumors, including hepatocellular carcinoma (HCC), which constitutes a solid barrier to effective anti-tumor immunity. A detailed characterization of exhaust...

    Authors: Jiaqiang Ma, Bohao Zheng, Shyamal Goswami, Lu Meng, Dandan Zhang, Chunmei Cao, Teng Li, Fangming Zhu, Lijie Ma, Zhao Zhang, Shuhao Zhang, Meng Duan, Qin Chen, Qiang Gao and Xiaoming Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:331

    Content type: Research article

    Published on:

  28. Pre-clinical and clinical studies have shown that the infusion of CAR T cells with a naive-like (TN) and central memory (TCM) phenotype is associated with prolonged in vivo T cell persistence and superior anti-tu...

    Authors: Alejandro Torres Chavez, Mary Kathryn McKenna, Emanuele Canestrari, Christina T. Dann, Carlos A. Ramos, Premal Lulla, Ann M. Leen, Juan F. Vera and Norihiro Watanabe

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:330

    Content type: Research article

    Published on:

  29. Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can ...

    Authors: Aliya Qayyum, Ken-Pin Hwang, Jason Stafford, Anuj Verma, Dipen M. Maru, Subramanya Sandesh, Jia Sun, Roberto Carmagnani Pestana, Rony Avritscher, Manal M. Hassan, Hesham Amin, Asif Rashid, Ignacio I. Wistuba, Richard L. Ehman, Jingfei Ma and Ahmed O. Kaseb

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:329

    Content type: Short report

    Published on:

  30. The ability to modulate immune-inhibitory pathways using checkpoint blockade antibodies such as αPD-1, αPD-L1, and αCTLA-4 represents a significant breakthrough in cancer therapy in recent years. This has driv...

    Authors: Molly A. Taylor, Adina M. Hughes, Josephine Walton, Anna M. L. Coenen-Stass, Lukasz Magiera, Lorraine Mooney, Sigourney Bell, Anna D. Staniszewska, Linda C. Sandin, Simon T. Barry, Amanda Watkins, Larissa S. Carnevalli and Elizabeth L. Hardaker

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:328

    Content type: Research article

    Published on:

  31. Programmed death-1 (PD-1) immune checkpoint blockade has achieved clinical successes in cancer therapy. However, the response rate of anti-PD-1 agents remains low. Additionally, a subpopulation of patients dev...

    Authors: Douglas D. Fang, Qiuqiong Tang, Yanhui Kong, Qixin Wang, Jiaxing Gu, Xu Fang, Peng Zou, Tao Rong, Jingwen Wang, Dajun Yang and Yifan Zhai

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:327

    Content type: Research article

    Published on:

  32. It is unclear whether plant-derived extracellular vesicles (EVs) can mediate interspecies communication with mammalian cells. Tumor-associated macrophages (TAMs) display a continuum of different polarization s...

    Authors: Meng Cao, Huaijiang Yan, Xuan Han, Ling Weng, Qin Wei, Xiaoyan Sun, Wuguang Lu, Qingyun Wei, Juan Ye, Xueting Cai, Chunping Hu, Xiaoyang Yin and Peng Cao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:326

    Content type: Research article

    Published on:

  33. The immunologic landscape of the host and tumor play key roles in determining how patients will benefit from immunotherapy, and a better understanding of these factors could help inform how well a tumor respon...

    Authors: Andrew B. Nixon, Kurt A. Schalper, Ira Jacobs, Shobha Potluri, I-Ming Wang and Catherine Fleener

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:325

    Content type: Review

    Published on:

  34. The IL-17 family cytokines are potent drivers of colorectal cancer (CRC) development. We and others have shown that IL-17 mainly signals to tumor cells to promote CRC, but the underlying mechanism remains uncl...

    Authors: Ju Chen, Xiaoyang Ye, Elise Pitmon, Mengqian Lu, Jun Wan, Evan R. Jellison, Adam J. Adler, Anthony T. Vella and Kepeng Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:324

    Content type: Research article

    Published on:

  35. Tumors that lack pre-existing immune infiltration respond poorly to T cell checkpoint blockade immunotherapy. These cancers often surround themselves with high densities of suppressive myeloid stroma while exc...

    Authors: Matthew J. Reilley, Brittany Morrow, Casey R. Ager, Arthur Liu, David S. Hong and Michael A. Curran

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:323

    Content type: Short report

    Published on:

  36. Hepatitis B virus (HBV) reactivation is a serious complication in patients with cancers and HBV infection undergoing immunosuppressant treatment or chemotherapy. However, the safety of anti-programmed cell dea...

    Authors: Xuanye Zhang, Yixin Zhou, Chen Chen, Wenfeng Fang, Xiuyu Cai, Xiaoshi Zhang, Ming Zhao, Bei Zhang, Wenqi Jiang, Zuan Lin, Yuxiang Ma, Yunpeng Yang, Yan Huang, Hongyun Zhao, Ruihua Xu, Shaodong Hong…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:322

    Content type: Research article

    Published on:

  37. Dendritic cell (DC) vaccine efficacy is directly related to the efficiency of DC migration to the lymph node after delivery to the patient. We discovered that a naturally occurring metabolite, sarcosine, incre...

    Authors: Farhad Dastmalchi, Aida Karachi, Changlin Yang, Hassan Azari, Elias Joseph Sayour, Anjelika Dechkovskaia, Alexander Loren Vlasak, Megan Ellen Saia, Rolando Eladio Lovaton, Duane Anthony Mitchell and Maryam Rahman

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:321

    Content type: Research article

    Published on:

  38. Tumour-associated macrophages (TAMs) are often implicated in cancer progression but can also exert anti-tumour activities. Selective eradication of cancer-promoting (M2-like) TAM subsets is a highly sought-aft...

    Authors: Eleanor M. Scott, Egon J. Jacobus, Brian Lyons, Sally Frost, Joshua D. Freedman, Arthur Dyer, Hena Khalique, William K. Taverner, Alison Carr, Brian R. Champion, Kerry D. Fisher, Len W. Seymour and Margaret R. Duffy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:320

    Content type: Research article

    Published on:

  39. Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is needed to aid in recognition and m...

    Authors: Houssein Safa, Daniel H Johnson, Van Anh Trinh, Theresa E Rodgers, Heather Lin, Maria E Suarez-Almazor, Faisal Fa’ak, Chantal Saberian, Cassian Yee, Michael A Davies, Sudhakar Tummala, Karin Woodman, Noha Abdel-Wahab and Adi Diab

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:319

    Content type: Research article

    Published on:

  40. Programmed cell death protein 1 (PD-1) blockade is only effective in a minority of patients, prompting the search for combinatorial therapies that increase responses. Identifying effective combinations require...

    Authors: Sandra Demaria, Emanuela Romano, Muriel Brackstone and Silvia C. Formenti

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:318

    Content type: Commentary

    Published on:

  41. Neurologic complications as myelitis are very rare but extremely deleterious adverse effects of both immunotherapy and radiotherapy. Many recent studies have focused on the possible synergy of these two treatm...

    Authors: Marcela Carausu, Arnaud Beddok, Adriana Langer, Nicolas Girard, François-Clément Bidard, Marie-Ange Massiani, Damien Ricard and Luc Cabel

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:317

    Content type: Case report

    Published on:

  42. Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that B...

    Authors: Lorenza Landi, Federica D’Incà, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:316

    Content type: Research article

    Published on:

  43. Hepatitis B virus (HBV) reactivation is commonly seen in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Little is known about the risk of HBV reactivation after chimeric antigen...

    Authors: Jia Wei, Xiaojian Zhu, Xia Mao, Liang Huang, Fankai Meng and Jianfeng Zhou

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:315

    Content type: Case report

    Published on:

  44. The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmaco...

    Authors: Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin and Sandhya Girish

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:314

    Content type: Research article

    Published on:

  45. The standard treatment for epithelial ovarian carcinoma (EOC) is surgery followed by platinum/paclitaxel-based chemotherapy, but the overall survival rate is poor. The purpose of this study was to investigate ...

    Authors: Yu-Li Chen, Han-Wei Lin, Chung-Liang Chien, Yen-Ling Lai, Wei-Zen Sun, Chi-An Chen and Wen-Fang Cheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:313

    Content type: Research article

    Published on:

  46. Adjuvanticity, which is the ability of neoplastic cells to deliver danger signals, is critical for the host immune system to mount spontaneous and therapy-driven anticancer immune responses. One of such signals, ...

    Authors: Lenka Kasikova, Michal Hensler, Iva Truxova, Petr Skapa, Jan Laco, Lucie Belicova, Ivan Praznovec, Sarka Vosahlikova, Michael J. Halaska, Tomas Brtnicky, Lukas Rob, Jiri Presl, Jan Kostun, Isabelle Cremer, Ales Ryska, Guido Kroemer…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:312

    Content type: Research article

    Published on:

  47. TNF receptor family agonists and checkpoint blockade combination therapies lead to minimal tumor clearance of poorly immunogenic tumors. Therefore, a need to enhance the efficacy of this combination therapy ar...

    Authors: Jaina M. Patel, Zhihua Cui, Zhi-Fa Wen, Catherine T. Dinh and Hong-Ming Hu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:311

    Content type: Research article

    Published on:

  48. Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomi...

    Authors: Alice Newey, Beatrice Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews, Sheela Rao, David Watkins, Ian Chau, George Coukos, Julien Racle, David Gfeller…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:309

    Content type: Research article

    Published on:

  49. Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events.

    Authors: J. Yang, S. M. Lagana, Y. M. Saenger and R. D. Carvajal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:310

    Content type: Case report

    Published on:

  50. Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous for reasons still needing to be elucidated. As the patient immune activity contributes to treatment clinical benefit, the p...

    Authors: Daniela Massi, Eliana Rulli, Mara Cossa, Barbara Valeri, Monica Rodolfo, Barbara Merelli, Francesco De Logu, Romina Nassini, Michele Del Vecchio, Lorenza Di Guardo, Roberta De Penni, Michele Guida, Vanna Chiarion Sileni, Anna Maria Di Giacomo, Marco Tucci, Marcella Occelli…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:308

    Content type: Research article

    Published on:

Advertisement

Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426